Literature DB >> 429494

The cyclic relationship of estrogen sulfurylation to the nuclear receptor level in human endometrial curettings.

B A Pack, R Tovar, E Booth, S C Brooks.   

Abstract

Human endometrial curettings were selected principally from patients undergoing tubal ligations for elective sterilization. Specimens were analyzed for the metabolism of 17beta-[6,7-3H]estradiol and Na2 35SO4; assayed for the nuclear receptor content with 17beta-[6,7-3H]estradiol; and examined for the cytosol receptor content with 17beta-[2,4,6,7-3H]estradiol. The results of these experiments demonstrated that a) estrogen sulfotransferase activity is greatly stimulated during the secretory phase; b) although estrogen dehydrogenase is active throughout the menstrual cycle, the formation of estrone is elevated in concert with sulfurylation; and c) this increased metabolism of 17beta-estradiol is accompanied by a decreased nuclear uptake of the estrogen receptor complex. The importance of this endometrial estrogen metabolism in the maintenance of a secretory tissue is discussed.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 429494     DOI: 10.1210/jcem-48-3-420

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  3 in total

1.  17 beta-Hydroxysteroid dehydrogenase type 2: chromosomal assignment and progestin regulation of gene expression in human endometrium.

Authors:  M L Casey; P C MacDonald; S Andersson
Journal:  J Clin Invest       Date:  1994-11       Impact factor: 14.808

2.  Development and characteristics of an oestrogen sulphotransferase in placenta and uterus of the pregnant mouse. Comparison between mouse and rat.

Authors:  R Hobkirk; C A Cardy; F Saidi; T G Kennedy; L R Girard
Journal:  Biochem J       Date:  1983-11-15       Impact factor: 3.857

3.  Estrone sulfate: a potential source of estradiol in human breast cancer tissues.

Authors:  S J Santner; D Leszczynski; C Wright; A Manni; P D Feil; R J Santen
Journal:  Breast Cancer Res Treat       Date:  1986       Impact factor: 4.872

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.